Dr. Colón has had a nearly 30-year career spanning biopharma, genomics, diagnostics, health care, digital health, synthetic biology, industrial biotechnology, venture capital, management consulting and entrepreneurship. Most recently, she co-founded Inaya Therapeutics, and previously served as CEO of InCarda Therapeutics, where she raised $120M and brought the lead program from pre-clinical stage to Phase 3. Prior to that she held leadership roles at Gilead Sciences, Intrexon, Affymetrix, and McKinsey, and she was a partner at New Science Ventures. She currently serves on the board of Voyager Therapeutics (NASDAQ: VYGR) and as chair of the boards of Bloom Science and Emm. She also serves on the Board of the MIT Corporation, and is a member of the Executive Committee of the Board of Directors of the Biotechnology Innovation Organization (BIO). Previously she served on the boards of CareDx (NASDAQ:CDNA), ProterixBio (Executive Chair), Paradigm Dx (acquired by Exact Sciences), Cocoon Biotech and PerceptiMed. She is a native of San Juan, Puerto Rico. She received her Ph.D. from the Massachusetts Institute of Technology and a B.S.E. from the University of Pennsylvania, both in chemical engineering. In 2024 she was elected a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).